Volrustomig Priming Regimens Exploratory Phase II Platform Study

Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.

Trial Details

NCT ID
NCT06448754
Phase
PHASE2
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Volrustomig
  • Carboplatin
  • Pemetrexed
  • Ramucirumab
  • Paclitaxel
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Grand Junction, Colorado, United States|39.06387,-108.55065
  • Wheat Ridge, Colorado, United States|39.7661,-105.07721
  • Baltimore, Maryland, United States|39.29038,-76.61219
  • Detroit, Michigan, United States|42.33143,-83.04575

Key Eligibility Criteria

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 with no deterioration.
  • Life expectancy greater than or equal to (\>=) 12 weeks.
  • Adequate organ and bone marrow function.
  • Body weight greater than (\>) 35 kilograms (kg) at screening and at randomization.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →